Outcome disparities in African American women with triple negative breast cancer: A comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Sturtz, Lori A ^a   Melley, Jen ^a   Mamula, Kim ^a   Shriver, Craig D ^b   Ellsworth, Rachel E ^c  

^a WINDBER RESEARCH INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICANS; ALCOHOL DRINKING; BETA-CRYSTALLIN B CHAIN; BREAST FEEDING; CAFFEINE; CHI-SQUARE DISTRIBUTION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIFE STYLE; MIDDLE AGED; OBESITY; RISK FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84893161185     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-62     Document Type: Article

References (38)

1. American Cancer Society Breast Cancer Facts and Figures 2011-2012 2011, Atlanta, GA: American Cancer Society, American Cancer Society.
2. Newman LA. Breast cancer in African-American women. Oncologist 2005, 10:1-14.
3. American Cancer Society Cancer Facts and Figures for African Americans 2009-2010 2009, Atlanta: American Cancer Society, American Cancer Society.
4. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4420-4434.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
6. Loo LWM, Wang Y, Flynn EM, Lung MJ, Bowles EJA, Buist DSM, et al. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat 2011, 127:297-308. 10.1007/s10549-010-1297-x, 3224104, 21264507.
7. Anders C, Carey LA. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008, 22:1233-1243. 2868264, 18980022.
8. Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE. Identification of differentially expressed genes in breast tumors from African American compared to Caucasian women. Cancer 2012, 118:1334-1344. 10.1002/cncr.26405, 21800289.
9. Martin DN, Boersma BJ, Yi M, Reimers M, Howe TM, Yfantis HG, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. Plos ONE 2009, 4:e4531. 10.1371/journal.pone.0004531, 2638012, 19225562.
10. Ellsworth RE, Zhu K, Bronfman L, Gutchell V, Hooke JA, Shriver CD. The Clinical Breast Care Project: an important resource in investigating environmental and genetic contributions to breast cancer in African American women. Cell Tissue Bank 2008, 9:109-120. 10.1007/s10561-007-9054-z, 17929197.
11. American Joint Committee on Cancer AJCC Cancer Staging Manual 2010, New York: Springer, 7, American Joint Committee on Cancer.
12. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957, 11:359-377. 10.1038/bjc.1957.43, 2073885, 13499785.
13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
14. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.
15. Retzlaff BM, Dowdy AA, Walden CE, Bovbjerg VE, Knopp RH. The Northwest Lipid Research Clinic fat intake scale: validation and utility. Am J Public Health 1997, 87:181-185. 10.2105/AJPH.87.2.181, 1380791, 9103094.
16. US Department of Health and Human Services 2008 Physical Activity Guidelines for Americans 2008, US Department of Health and Human Services.
17. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
18. Jatoi I, Becher H, Leake CR. Widening disparity in survival between White and African-American patients with breast carcinoma treated in the US Department of Defense healthcare system. Cancer 2003, 98:894-899. 10.1002/cncr.11604, 12942554.
19. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16:6100-6110. 10.1158/1078-0432.CCR-10-1533, 3029098, 21169259.
20. Pacheco JM, Gao F, Bumb C, Ellis MJ, Ma CX. Racial differences in outcomes of triple-negative breast cancer. Breast Cancer Res Treat 2013, 138:281-289. 10.1007/s10549-012-2397-6, 23400579.
21. Brakenhoff RH, Aarts HJ, Schuren F, Lubsen NH, Schoenmakers JG. The second human beta B2-crystallin gene is a pseudogene. Exp Eye Res 1992, 54:803-806. 10.1016/0014-4835(92)90036-R, 1623966.
22. Jovov B, Araujo-Perez F, Sigel CS, Stratford JK, McCoy AN, Yeh JJ, et al. Differential gene expression between African American and European American colorectal cancer patients. Plos ONE 2012, 7:e30168. 10.1371/journal.pone.0030168, 3261881, 22276153.
23. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008, 68:927-936. 10.1158/0008-5472.CAN-07-2608, 18245496.
24. Wei P, Milbauer LC, Enenstein J, Nguyen J, Pan W, Hebbel RP. Differential endothelial cell gene expression by African Americans versus Caucasian Americans: a possible contribution to health disparity in vascular disease and cancer. BMC Med 2011, 9:2. 10.1186/1741-7015-9-2, 3029215, 21223544.
25. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2013, 43:1210-1214.
26. Palmer JR, Ruiz-Navarez EA, Rotimi CM, Cupples LA, Cozier YC, Adams-Campbell LL, et al. Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prev 2013, 22:127-134. 10.1158/1055-9965.EPI-12-0769, 3538887, 23136140.
27. Baker JA, Beehler GP, Sawant AC, Jayaprakash V, McCann SE, Moysich KB. Consumption of coffee, but not black tea, is associated with decreased risk of premenopausal breast cancer. J Nutr 2006, 136:166-171.
28. Boggs DA, Palmer JR, Stampfer MJ, Spiegelman D, Adams-Campbell LL, Rosenberg L. Tea and coffee intake in relation to risk of breast cancer in the Black Women's Health Study. Cancer Causes Control 2010, 21:1941-1948. 10.1007/s10552-010-9622-6, 3152948, 20680436.
29. Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, et al. Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control 2011, 22:775-783. 10.1007/s10552-011-9750-7, 3100347, 21360045.
30. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011, 103:250-263. 10.1093/jnci/djq526, 3107570, 21191117.
31. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008, 17:2078-2086. 10.1158/1055-9965.EPI-08-0206, 2561180, 18664548.
32. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Smith LV, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139. 10.1007/s10549-007-9632-6, 2443103, 17578664.
33. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013, 137:307-314. 10.1007/s10549-012-2339-3, 23179600.
34. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010, 116:4933-4943. 10.1002/cncr.25443, 20665494.
35. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 2008, 113:1521-1526. 10.1002/cncr.23786, 2587413, 18726992.
36. Li CI, Beaber EF, Tang M-TC, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat 2013, 137:579-587. 10.1007/s10549-012-2365-1, 3547981, 23224237.
37. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009, 11:R31. 10.1186/bcr2261, 2716499, 19463150.
38. Toumoux C, Katsahian S, Chevret S, Levy V. Factors influencing inclusion of patients with malignancies in clinical trials: a review. Cancer 2006, 106:258-270. 10.1002/cncr.21613, 16397866.